Xenetic Biosciences PLC : Director Dealings

6 January 2014

Xenetic Biosciences plc ("Xenetic" or the "Company")

Directors Dealings

Xenetic Bio (AIM: XEN.L), a bio-pharmaceutical company specialising in the development of high-value differentiated biologics, vaccines and novel cancer drugs, was informed on 23 December 2013 of the following dealings by Directors and their connected persons ("Dealings"). The dealings took place on 20 December 2013, at a price of 4.5 pence per ordinary shares of 0.5 pence each ("Ordinary Shares") in the Company.

Director	Beneficial holding of Ordinary Shares prior to the Dealings	% of share capital prior to the Dealings	Shares acquired	Beneficial holding of Ordinary Shares following the Dealings	% beneficial holding of Ordinary Shares following the Dealings
Scott Maguire	1,401,361	0.34	25,000	1,426,361	0.35
Colin Hill	1,825,420	0.45	50,000	1,875,420	0.46

The Company's issued share capital consists of 408,048,487 Ordinary Shares with voting rights. The Company does not hold any Ordinary shares in treasury.

Enquiries:

Xenetic Biosciences plc	www.xeneticbio.com
M. Scott Maguire, Chief Executive Officer	[phone]
Colin Hill, Chief Financial Officer
London Bridge Capital (Financial Adviser to Xenetic)	[phone]
Adam Hart
N+1 Singer(Nominated Adviser & Broker)	[phone]
Aubrey Powell
Walbrook PR	[phone]
Mike Wort (Media Enquiries)	[e-mail]
Paul Cornelius (Investor Enquiries)	[e-mail]

This information is provided by RNS

The company news service from the London Stock Exchange

ENDRDSBUGDBSBGBGSL